Newsroom

LYON, Francia--(BUSINESS WIRE)--Brenus Pharma, una empresa de biotecnología en fase clínica que se dedica a liberar el potencial del sistema inmunitario in vivo para combatir los tumores sólidos, ha anunciado que han concluido con éxito los primeros niveles de dosis en su primer estudio en humanos, que actualmente se encuentra en curso. Este ensayo multicéntrico y abierto (NCT06934538) es un estudio de fase Ia/Ib diseñado para evaluar el perfil de seguridad, tolerabilidad y la actividad clínica...

TORONTO--(BUSINESS WIRE)--Primaris Real Estate Investment Trust (“Primaris” or the “Trust”) (TSX: PMZ.UN) announced today that its Board of Trustees has declared a distribution of $0.07333 per unit for the month of January 2026, representing $0.88 per unit on an annualized basis. The distribution will be payable on February 17, 2026 to unitholders of record on January 30, 2026. About Primaris Real Estate Investment Trust Primaris is Canada’s only enclosed shopping centre focused REIT, with owne...

PASADENA, Calif.--(BUSINESS WIRE)--Tetra Tech, Inc. (NASDAQ: TTEK), a leading provider of high-end consulting and engineering services in water, environment, and sustainable infrastructure, announced today the planned dates for its first quarter 2026 results and conference call. On Wednesday, January 28, 2026, after market close, Tetra Tech intends to announce its first quarter 2026 results. On Thursday, January 29, 2026, at 8:00 a.m. Pacific Time, Tetra Tech plans to host a conference call to...

MADISON, Wis.--(BUSINESS WIRE)--First Business Financial Services, Inc. (the “Company” or “First Business Bank”) (Nasdaq:FBIZ) invites participation in a conference call to discuss the Company’s financial and operating performance during its fourth quarter ended December 31, 2025. The conference call and webcast may contain forward-looking statements and other material information. Event: Earnings Conference Call – Fourth Quarter 2025 When: Friday, January 30, 2026 at 1:00 p.m. Central Time How...

SAN CARLOS, Kalifornien, USA--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute die vollständigen Ergebnisse der Phase-3-Studie HERIZON-GEA-01 bekannt. Die Studie untersuchte ZIIHERA® (Zanidatamab), einen HER2-gerichteten bispezifischen Antikörper, in Kombination mit einer Chemotherapie mit und ohne den PD-1-Inhibitor TEVIMBRA® (Tislelizumab) als Erstlinienbehandlung für ein HER2-positives (HER2+) lokal fortgeschr...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy los resultados completos del ensayo de Fase 3 HERIZON-GEA-01, que evaluó ZIIHERA® (zanidatamab), un anticuerpo biespecífico dirigido a HER2, en combinación con quimioterapia, con y sin el inhibidor de PD-1 TEVIMBRA® (tislelizumab), como tratamiento de primera línea para adenocarcinoma gástrico y esofágico HER2 positivo (HER2+) localmente avanzado o meta...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda oncologica globale, oggi ha annunciato i risultati completi dello studio di fase 3 HERIZON-GEA-01 volto a valutare ZIIHERA® (zanidatamab), un anticorpo bispecifico mirato a HER2, in combinazione con chemioterapia, con e senza l'inibitore di PD-1 TEVIMBRA® (tislelizumab), come trattamento di prima linea nell'adenocarcinoma gastroesofageo (GEA) localmente avanzato o metastatico con espressio...

LIVONIA, Mich.--(BUSINESS WIRE)--Trinity Health today announced that it delivered $2.9 billion in programs and services during fiscal year 2025, reaffirming its commitment to patients and communities despite significant pressures facing the health care industry. Investments made across Trinity Health’s 25-state footprint include covering $310 million in care costs helping nearly 450,000 patients receive necessary routine and emergency care; completing more than 1 million screenings to identify...

LYON, France--(BUSINESS WIRE)--  Brenus Pharma annonce une tolérance favorable et des signaux cliniques positifs dans les premiers résultats préliminaires de son étude de première administration chez l'homme évaluant le STC-1010 chez des patients atteints d'un cancer colorectal métastatique non résécable (MSS CRC) Brenus Pharma, une société de biotechnologie en phase clinique qui active le système immunitaire in vivo pour lutter contre les tumeurs solides, a annoncé la réussite des premiers niv...

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to OHS Issuer, LLC, Series 2026-1/2 (OHS 2026-1/2 or the Series 2026-1/2 Notes), a service contract securitization that is primarily collateralized by home service contracts. OHS 2026-1/2 represents OHS Issuer, LLC’s (the Issuer) first securitization. The transaction structure is a master trust, and as such, the indenture permits the issuance of additional classes and series of notes subject to certain conditions, including rating agen...